Cited 5 times in
Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박기청 | - |
dc.contributor.author | 윤혁준 | - |
dc.contributor.author | 장항석 | - |
dc.contributor.author | 장호진 | - |
dc.contributor.author | 황성순 | - |
dc.date.accessioned | 2022-03-11T06:22:52Z | - |
dc.date.available | 2022-03-11T06:22:52Z | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 1661-6596 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/188061 | - |
dc.description.abstract | Thyroid cancer (TC) includes tumors of follicular cells; it ranges from well differentiated TC (WDTC) with generally favorable prognosis to clinically aggressive poorly differentiated TC (PDTC) and undifferentiated TC (UTC). Papillary thyroid cancer (PTC) is a WDTC and the most common type of thyroid cancer that comprises almost 70-80% of all TC. PTC can present as a solid, cystic, or uneven mass that originates from normal thyroid tissue. Prognosis of PTC is excellent, with an overall 10-year survival rate >90%. However, more than 30% of patients with PTC advance to recurrence or metastasis despite anti-cancer therapy; consequently, systemic therapy is limited, which necessitates expansion of improved clinical approaches. We strived to elucidate genetic distinctions due to patient-derived anti-cancer drug-sensitive or -resistant PTC, which can support in progress novel therapies. Patients with histologically proven PTC were evaluated. PTC cells were gained from drug-sensitive and -resistant patients and were compared using mRNA-Seq. We aimed to assess the in vitro and in vivo synergistic anti-cancer effects of a novel combination therapy in patient-derived refractory PTC. This combination therapy acts synergistically to promote tumor suppression compared with either agent alone. Therefore, genetically altered combination therapy might be a novel therapeutic approach for refractory PTC. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.publisher | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antineoplastic Agents / therapeutic use* | - |
dc.subject.MESH | Drug Resistance, Neoplasm* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Gene Expression Regulation, Neoplastic* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Paclitaxel / therapeutic use | - |
dc.subject.MESH | Phenylurea Compounds / therapeutic use | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Quinolines / therapeutic use | - |
dc.subject.MESH | RNA-Seq | - |
dc.subject.MESH | Sorafenib / therapeutic use | - |
dc.subject.MESH | Thyroid Cancer, Papillary / drug therapy* | - |
dc.subject.MESH | Thyroid Cancer, Papillary / genetics | - |
dc.subject.MESH | Thyroid Cancer, Papillary / physiopathology | - |
dc.subject.MESH | Xenograft Model Antitumor Assays | - |
dc.title | Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Hyeok Jun Yun | - |
dc.contributor.googleauthor | Minki Kim | - |
dc.contributor.googleauthor | Sang Yong Kim | - |
dc.contributor.googleauthor | Sungsoon Fang | - |
dc.contributor.googleauthor | Yonjung Kim | - |
dc.contributor.googleauthor | Hang-Seok Chang | - |
dc.contributor.googleauthor | Ho-Jin Chang | - |
dc.contributor.googleauthor | Ki Cheong Park | - |
dc.identifier.doi | 10.3390/ijms23020699 | - |
dc.contributor.localId | A01449 | - |
dc.contributor.localId | A06022 | - |
dc.contributor.localId | A03488 | - |
dc.contributor.localId | A03496 | - |
dc.contributor.localId | A05443 | - |
dc.relation.journalcode | J01133 | - |
dc.identifier.eissn | 1422-0067 | - |
dc.identifier.pmid | 35054884 | - |
dc.subject.keyword | EMT | - |
dc.subject.keyword | FGFR | - |
dc.subject.keyword | drug-resistant papillary thyroid cancer | - |
dc.subject.keyword | lenvatinib | - |
dc.subject.keyword | paclitaxel | - |
dc.subject.keyword | patient-derived papillary thyroid cancer | - |
dc.subject.keyword | sorafenib | - |
dc.contributor.alternativeName | Park, Ki Cheong | - |
dc.contributor.affiliatedAuthor | 박기청 | - |
dc.contributor.affiliatedAuthor | 윤혁준 | - |
dc.contributor.affiliatedAuthor | 장항석 | - |
dc.contributor.affiliatedAuthor | 장호진 | - |
dc.contributor.affiliatedAuthor | 황성순 | - |
dc.citation.volume | 23 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 699 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, Vol.23(2) : 699, 2022-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.